Korbinian Nepomuk. Kropp
Research Subjects
Korbinian Nepomuk. Kropp has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Christopher A. Klebanoff
Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA
2 shared publications - Abraham Ari Hakimi
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication - Alexander Roesch
Department of Dermatology, University Hospital Essen, 45147 Essen, Germany
1 shared publication - Alicia Brüggemann
Essen University Hospital 3 Essen
1 shared publication Andreas D. Hartkopf
Department of Obstetrics and Gynecology, University Hospital Tuebingen, Tuebingen, Germany
1 shared publication- Andreas Heinold
Essen University Hospital 3 Essen
1 shared publication
Latest Publications
- Open Access
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
A functional TIGIT-associated transcriptional program identifies circulating tumor-reactive CD8⁺ T cells in melanoma patients
Accessing tumor-reactive CD8⁺ T cells in patient blood is essential for non-invasive monitoring of systemic T cell responses and guiding personalized therapies. However, precise functional, molecular, and phenotypic characterization of these cells remains challenging. Here, we identify TIGIT as a functionally validated surrogate marker of tumor-reactive CD8⁺ T cells and define its associated transcriptional program to characterize circulating tumor-reactive CD8⁺ T cells in melanoma patients. We demonstrate that blood TIGIT⁺ CD8⁺ T cells mount robust cytotoxic responses against autologous tumor cells across multiple melanoma patient models, irrespective of PD-1 co-expression. At the clonotype level, TIGIT broadened detection of the circulating tumor-reactive repertoire beyond PD-1 while retaining high specificity. Moreover, circulating TIGIT⁺ CD8⁺ T cell population was closely associated with the intratumoral T cell repertoire and exhibited hallmarks of antigen experience, including effector memory differentiation, a hypomethylated DNA landscape, and increased clonal expansion. Longitudinal profiling of blood samples from melanoma patients undergoing immune checkpoint inhibition revealed an increased frequency of TIGIT⁺ CD8⁺ T cells in clinical responders. Finally, leveraging paired single-cell transcriptomic and TCR data from patient models with identified tumor-reactive clones, we show that the TIGIT-associated transcriptional program enables robust detection of circulating tumor-reactive CD8⁺ T cells. Collectively, our data establish TIGIT⁺ CD8⁺ T cells as a potent reservoir of tumor-reactive T cells in peripheral blood and provide a blood-based framework for accelerating TCR discovery and advancing adoptive cell therapy.
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
Open AccessA functional TIGIT-associated transcriptional program identifies circulating tumor-reactive CD8⁺ T cells in melanoma patients
Accessing tumor-reactive CD8⁺ T cells in patient blood is essential for non-invasive monitoring of systemic T cell responses and guiding personalized therapies. However, precise functional, molecular, and phenotypic characterization of these cells remains challenging. Here, we identify TIGIT as a functionally validated surrogate marker of tumor-reactive CD8⁺ T cells and define its associated transcriptional program to characterize circulating tumor-reactive CD8⁺ T cells in melanoma patients. We demonstrate that blood TIGIT⁺ CD8⁺ T cells mount robust cytotoxic responses against autologous tumor cells across multiple melanoma patient models, irrespective of PD-1 co-expression. At the clonotype level, TIGIT broadened detection of the circulating tumor-reactive repertoire beyond PD-1 while retaining high specificity. Moreover, circulating TIGIT⁺ CD8⁺ T cell population was closely associated with the intratumoral T cell repertoire and exhibited hallmarks of antigen experience, including effector memory differentiation, a hypomethylated DNA landscape, and increased clonal expansion. Longitudinal profiling of blood samples from melanoma patients undergoing immune checkpoint inhibition revealed an increased frequency of TIGIT⁺ CD8⁺ T cells in clinical responders. Finally, leveraging paired single-cell transcriptomic and TCR data from patient models with identified tumor-reactive clones, we show that the TIGIT-associated transcriptional program enables robust detection of circulating tumor-reactive CD8⁺ T cells. Collectively, our data establish TIGIT⁺ CD8⁺ T cells as a potent reservoir of tumor-reactive T cells in peripheral blood and provide a blood-based framework for accelerating TCR discovery and advancing adoptive cell therapy.
- Open Access
A post-translational regulatory map of chronic antigen-driven human T cell dysfunction
SUMMARY: T cells exposed to persistent antigen in the context of chronic viral infections or cancer lose self-renewal and cytotoxic capacity. Several transcriptional, epigenetic, and metabolic drivers of this process have been identified. However, the post-transcriptional regulatory mechanisms influencing the proteome of dysfunctional T cells are not well understood. Here we present a time-resolved molecular landscape of human T cells during the development of chronic antigen-driven dysfunction. Persistent T cell receptor stimulation significantly remodeled the proteome, including changes in canonical T cell exhaustion-associated proteins and proteins related to mitochondrial function, redox homeostasis, nucleotide metabolism, and cell-cycle progression. Dysfunctional T cells displayed activation of stress response pathways that were recapitulated in vivo ; targeting these pathways altered the cytotoxic capacity of T cells during persistent tumor exposure. Our comprehensive proteomic resource reveals unique post-transcriptional changes in dysfunctional T cells and lays the groundwork for novel cysteine-directed therapeutics to enhance cancer immunotherapy.
Open AccessA post-translational regulatory map of chronic antigen-driven human T cell dysfunction
SUMMARY: T cells exposed to persistent antigen in the context of chronic viral infections or cancer lose self-renewal and cytotoxic capacity. Several transcriptional, epigenetic, and metabolic drivers of this process have been identified. However, the post-transcriptional regulatory mechanisms influencing the proteome of dysfunctional T cells are not well understood. Here we present a time-resolved molecular landscape of human T cells during the development of chronic antigen-driven dysfunction. Persistent T cell receptor stimulation significantly remodeled the proteome, including changes in canonical T cell exhaustion-associated proteins and proteins related to mitochondrial function, redox homeostasis, nucleotide metabolism, and cell-cycle progression. Dysfunctional T cells displayed activation of stress response pathways that were recapitulated in vivo ; targeting these pathways altered the cytotoxic capacity of T cells during persistent tumor exposure. Our comprehensive proteomic resource reveals unique post-transcriptional changes in dysfunctional T cells and lays the groundwork for novel cysteine-directed therapeutics to enhance cancer immunotherapy.
- Open Access
CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit
Chimeric antigen receptor (CAR)-engineered T and NK cells can cause durable remission of B-cell malignancies; however, limited persistence restrains the full potential of these therapies in many patients. The FAS ligand (FAS-L)/FAS pathway governs naturally-occurring lymphocyte homeostasis, yet knowledge of which cells express FAS-L in patients and whether these sources compromise CAR persistence remains incomplete. Here, we constructed a single-cell atlas of diverse cancer types to identify cellular subsets expressing FASLG , the gene encoding FAS-L. We discovered that FASLG is limited primarily to endogenous T cells, NK cells, and CAR-T cells while tumor and stromal cells express minimal FASLG . To establish whether CAR-T/NK cell survival is regulated through FAS-L, we performed competitive fitness assays using lymphocytes modified with or without a FAS dominant negative receptor (ΔFAS). Following adoptive transfer, ΔFAS-expressing CAR-T and CAR-NK cells became enriched across multiple tissues, a phenomenon that mechanistically was reverted through FASLG knockout. By contrast, FASLG was dispensable for CAR-mediated tumor killing. In multiple models, ΔFAS co-expression by CAR-T and CAR-NK enhanced antitumor efficacy compared with CAR cells alone. Together, these findings reveal that CAR-engineered lymphocyte persistence is governed by a FAS-L/FAS auto-regulatory circuit.
Open AccessCAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit
Chimeric antigen receptor (CAR)-engineered T and NK cells can cause durable remission of B-cell malignancies; however, limited persistence restrains the full potential of these therapies in many patients. The FAS ligand (FAS-L)/FAS pathway governs naturally-occurring lymphocyte homeostasis, yet knowledge of which cells express FAS-L in patients and whether these sources compromise CAR persistence remains incomplete. Here, we constructed a single-cell atlas of diverse cancer types to identify cellular subsets expressing FASLG , the gene encoding FAS-L. We discovered that FASLG is limited primarily to endogenous T cells, NK cells, and CAR-T cells while tumor and stromal cells express minimal FASLG . To establish whether CAR-T/NK cell survival is regulated through FAS-L, we performed competitive fitness assays using lymphocytes modified with or without a FAS dominant negative receptor (ΔFAS). Following adoptive transfer, ΔFAS-expressing CAR-T and CAR-NK cells became enriched across multiple tissues, a phenomenon that mechanistically was reverted through FASLG knockout. By contrast, FASLG was dispensable for CAR-mediated tumor killing. In multiple models, ΔFAS co-expression by CAR-T and CAR-NK enhanced antitumor efficacy compared with CAR cells alone. Together, these findings reveal that CAR-engineered lymphocyte persistence is governed by a FAS-L/FAS auto-regulatory circuit.
- Open Access
- 4 February 2021
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (9) , 2483-2496
Platelet-expressed immune checkpoint regulator GITRL in breast cancer
Owing to their key role in several diseases including cancer, activating and inhibitory immune checkpoint molecules are increasingly exploited as targets for immunotherapy. Recently, we demonstrated that platelets, which largely influence tumor progression and immune evasion, functionally express the ligand of the checkpoint molecule GITR. This immunoreceptor modulates effector functions of T cells and NK cells with its function varying dependent on cellular context and activation state. Here, we provide a comparative analysis of platelet-derived GITRL (pGITRL) in breast cancer patients and healthy volunteers. The levels of pGITRL were found to be higher on platelets derived from cancer patients and appeared to be specifically regulated during tumor progression as exemplified by several clinical parameters including tumor stage/grade, the occurrence of metastases and tumor proliferation (Ki67) index. In addition, we report that pGITRL is upregulated during platelet maturation and particularly induced upon exposure to tumor-derived soluble factors. Our data indicate that platelets modulate the GITR/GITRL immune checkpoint in the context of malignant disease and provide a rationale to further study the GITR/GITRL axis for exploitation for immunotherapeutic intervention in cancer patients.
- 4 February 2021
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (9) , 2483-2496
Open AccessPlatelet-expressed immune checkpoint regulator GITRL in breast cancer
Owing to their key role in several diseases including cancer, activating and inhibitory immune checkpoint molecules are increasingly exploited as targets for immunotherapy. Recently, we demonstrated that platelets, which largely influence tumor progression and immune evasion, functionally express the ligand of the checkpoint molecule GITR. This immunoreceptor modulates effector functions of T cells and NK cells with its function varying dependent on cellular context and activation state. Here, we provide a comparative analysis of platelet-derived GITRL (pGITRL) in breast cancer patients and healthy volunteers. The levels of pGITRL were found to be higher on platelets derived from cancer patients and appeared to be specifically regulated during tumor progression as exemplified by several clinical parameters including tumor stage/grade, the occurrence of metastases and tumor proliferation (Ki67) index. In addition, we report that pGITRL is upregulated during platelet maturation and particularly induced upon exposure to tumor-derived soluble factors. Our data indicate that platelets modulate the GITR/GITRL immune checkpoint in the context of malignant disease and provide a rationale to further study the GITR/GITRL axis for exploitation for immunotherapeutic intervention in cancer patients.
- Open Access
- 9 September 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (9) , e0238875
A bicistronic vector backbone for rapid seamless cloning and chimerization of αβT-cell receptor sequences
To facilitate preclinical testing of T-cell receptors (TCRs) derived from tumor-reactive T-cell clones it is necessary to develop convenient and rapid cloning strategies for the generation of TCR expression constructs. Herein, we describe a pDONR™221 vector backbone allowing to generate Gateway™ compatible entry clones encoding optimized bicistronic αβTCR constructs. It harbors P2A-linked TCR constant regions and head-to-head-oriented recognition sites of the Type IIS restriction enzymes BsmBI and BsaI for seamless cloning of the TCRα and TCRβ V(D)J regions, respectively. Additional well-established TCR optimizations were incorporated to enhance TCR functionality. This included replacing of the human αβTCR constant regions with their codon-optimized murine counterparts for chimerization, addition of a second interchain disulfide bond and arrangement of the TCR chains in the order β-P2A-α. We exemplified the utility of our vector backbone by cloning and functional testing of three melanoma-reactive TCRs in primary human T cells.
- 9 September 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (9) , e0238875
Open AccessA bicistronic vector backbone for rapid seamless cloning and chimerization of αβT-cell receptor sequences
To facilitate preclinical testing of T-cell receptors (TCRs) derived from tumor-reactive T-cell clones it is necessary to develop convenient and rapid cloning strategies for the generation of TCR expression constructs. Herein, we describe a pDONR™221 vector backbone allowing to generate Gateway™ compatible entry clones encoding optimized bicistronic αβTCR constructs. It harbors P2A-linked TCR constant regions and head-to-head-oriented recognition sites of the Type IIS restriction enzymes BsmBI and BsaI for seamless cloning of the TCRα and TCRβ V(D)J regions, respectively. Additional well-established TCR optimizations were incorporated to enhance TCR functionality. This included replacing of the human αβTCR constant regions with their codon-optimized murine counterparts for chimerization, addition of a second interchain disulfide bond and arrangement of the TCR chains in the order β-P2A-α. We exemplified the utility of our vector backbone by cloning and functional testing of three melanoma-reactive TCRs in primary human T cells.